AUTL

Autolus Therapeutics

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United Kingdom

Next Earnings Date

05/14/26

Business Summary

Autolus Therapeutics is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for cancer. It generates cash primarily through capital markets financing while advancing proprietary cell therapy candidates through clinical trials with the aim of eventual commercialization or partnership monetization. Its moat is rooted in intellectual property around engineered cell programming and manufacturing know-how, which are complex, regulated, and difficult to replicate at scale. If successful, value creation comes from high-margin biologic therapies with strong pricing power, but until approval and commercialization, the model remains capital intensive and milestone dependent.

VALUATION

P/E

-

Market Cap ($M USD)

$396

Forward P/E

-

PEG

-

PRICE TO SALES

5.3

PRICE TO BOOK

2.2

EV / EBITDA

-0.7

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$1.08

Next Year EPS Growth Estimate

-$0.73

Next Year Revenue Growth Estimate

53.50%

Return on Equity (ROE)

-161.40%

Operating Margin

-358.90%

Debt-to-Equity

0.4

Piotroski F-Score

4

Altman Z-Score

-3.4

Return on Invested Capital (ROIC)

-75.00%%

Current Ratio

5.9

Quick Ratio

Gainseekers Quantitative Analysis

Summary

At a $396M market cap with no P/E or Forward P/E and an Altman Z-Score of -3.4, this is a balance-sheet distressed, pre-profit biotech—not a mispriced compounder. The absence of earnings, EPS of -0.7, EPS next year estimated at -$1.08, and an operating margin of -161.40% signal a company still deeply in capital-consuming mode. A Price/Sales of 5.3 and Price/Book of 2.2 are not cheap given ROIC of -75.00% and negative forward earnings power. This is a high-risk development-stage equity where solvency risk overwhelms any traditional valuation anchor.

AI Exposure / Tech Reliance

As a Biotechnology company in Healthcare, AUTL operates in a sector where AI-driven drug discovery, patient stratification, and trial optimization are becoming table stakes. The industry’s shift toward data-intensive precision therapies structurally favors companies that can integrate computational biology into development workflows. However, financial metrics here reflect R&D intensity rather than scaled technological monetization.

The Bull Case

A deep-value or speculative GARP investor could argue the balance sheet liquidity is not immediately stressed, with a strong Current Ratio of 5.9 providing short-term operational runway. Despite negative earnings, Return on Equity stands at 53.50%, which—paired with a Piotroski F-Score of 4—suggests the company is not in total operational freefall and may be in a transitional capital structure phase. Institutional Ownership listed at $8.77 and a Consensus Rating of 8.50% imply at least some level of professional sponsorship and constructive outlook. In a binary biotech setup, a $396M market cap leaves asymmetrical upside if pipeline execution inflects revenue beyond the currently negative Sales Growth Next Year figure of -$0.73.

The Bear Case

The bear case is brutal: Operating Margin of -161.40% and ROIC of -75.00% confirm systematic value destruction. Debt/Equity at -358.90% combined with an Altman Z-Score of -3.4 screams balance sheet fragility and potential recapitalization risk. There is no P/E, no Forward P/E, no PEG, and EPS is projected to worsen to -$1.08, meaning fundamental profitability is moving in the wrong direction. A Price/Sales of 5.3 for a company with negative growth next year and no dividend support (Dividend 5-Year Avg 0, Dividend Per Share USD -) is aggressive for a business still burning capital.

Market Sentiment & Smart Money

Short Interest %

8.50%

Analyst Consensus

1.27

Average Analyst Price Target

$8.77

Institutional Ownership %

77.70%

1-Year Beta

1.87

Insider Buying % (6 Mo)

5.60%%

Distance to 52-Week High

55.20%%

Distance to 52-Week Low

134.80%%